---
title: "Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Product comparison"
description: "Formulary evidence on Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Product comparison. Topics: Company cross-trial comparison with approved agents in CIS-containing BCG-unresponsive disease, Company caveat on cross-trial comparisons, Guideline table of bladder-sparing options for carcinoma in situ with or without papillary disease, Re-induction at 3 months as a difference in trial design, and 4 further topics. 8 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description/product-comparison"
published: "2026-11-18T10:43:03-05:00"
modified: "2026-11-18T10:43:03-05:00"
---

# Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Product comparison

<a id="heading-2.1.2.14"></a>

## 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

### Company cross-trial comparison with approved agents in CIS-containing BCG-unresponsive disease

| Feature | Cretostimogene | TAR-200 | N-803 + BCG | Nadofaragene | Pembrolizumab |
| --- | --- | --- | --- | --- | --- |
| Mechanism | “Oncolytic Immunotherapy” | “Gemcitabine via In-Dwelling Device” | “IL-15 Superagonist + BCG combo” | “Gene Therapy Secreting IFN” | “Checkpoint Inhibitor” |
| Route of administration | “Intravesical” | “Transurethral Procedure” | “Intravesical” | “Intravesical” | “Intravenous” |
| CR at any time | “75.5% (83/110)” | “82.4% (70/83)” | “62.3% (48/77)” | “51.0% (50/98)” | “40.6% (39/96)” |
| CR at 12 months | “46.4% (51/110)” | “K-M: 45.9% (39/83)” | “36.4% (28/77)” | “24.3% (25/103)” | “18.8% (18/96)” |
| CR at 24 months | “41.8% (46/110)” | “Not Reported” | “24.7% (19/77)” | “19.4% (20/103)” | “9.4% (9/96)” |
| Grade 3 or higher treatment-related adverse events | “0%” | “13%” | “Not reported; 16% SAE” | “4%” | “13%” |
| Treatment-related discontinuation | “0%” | “3.5%” | “7%” | “3%” | “11%” |

Source: [CG Oncology investor presentation (2026)](https://ir.cgoncology.com/static-files/16380a7a-42d9-40fc-a2a5-03e0b5235ed3)

<a id="topic-2.1.2.14-2"></a>

### Company caveat on cross-trial comparisons

> “These data are not based on head-to-head or comparator studies. Differences exist between study designs and subject characteristics, and caution should be exercised when comparing data across studies.”

Source: [CG Oncology investor presentation (2026)](https://ir.cgoncology.com/static-files/16380a7a-42d9-40fc-a2a5-03e0b5235ed3)

<a id="topic-2.1.2.14-3"></a>

### Guideline table of bladder-sparing options for carcinoma in situ with or without papillary disease

| Compound | Study design | n | Follow-up (months) | CR at 3 months (%) | CR at 6 months (%) | CR at 12 months (%) | Adverse events |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Nadofaragene firadenovec | “Phase III Cis Cohort” | “103” | “19.7” | “53.4” | “40.8” | “24.3” | “G3 4%” |
| Cretostimogene grenadenorepvec (CG0070) | “Phase II” | “45” | Not reported | Not reported | “58 CIS”; “50 CIS+P” | Not reported | “G1-2 82.5% G ≥ 3 4.5%” |
| Nogapendekin alfa inbakicept plus BCG | “Phase II/III QUILT 3032 CA” | “82” | “23.9” | “55.0” | “56.0” | “45.0” | “G1-2 86% G ≥ 3 23%” |
| TAR-200 | “Phase II b SunRISe-1 C2” | “81” | “20.2” | “78.8” | “58.8” | “45.9” | “Any G 83.5% G ≥ 3 12.9%” |
| Pembrolizumab | “Phase II Cohort A KEYNOTE-057” | “96” | “36.4” | “41.0” | Not reported | “18.7” | “G1-2 53.0% G ≥ 3 13%” |

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

<a id="topic-2.1.2.14-4"></a>

### Re-induction at 3 months as a difference in trial design

> “Recently, a CR rate of 75% was reported for the investigational agent cretostimogene grenadenorepvec in patients with BCG-unresponsive CIS, although this CR rate included patients with persistent disease who underwent repeat induction treatment, which was not permitted in SunRISe-1.”
> “Acknowledging the limitations of indirect cross-study comparisons, TAR-200 was associated with a higher CR rate than both conventional gemcitabine instillation and FDA-approved novel agents (pembrolizumab, nadofaragene firadenovec, and NAI + BCG), ranging from 41% to 62%.”

Source: [Daneshmand et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12622271/)

<a id="topic-2.1.2.14-5"></a>

### Nadofaragene firadenovec: indication, dosing, and efficacy in prescribing information

| Feature | Quoted label text |
| --- | --- |
| Indication | “(BCG)-unresponsive non-Muscle Invasive Bladder Cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors” |
| Dosing interval | “instilled once every three (3) months into the bladder via a urinary catheter” |
| Premedication | “Premedication with an anticholinergic is recommended before each instillation of ADSTILADRIN.” |
| Complete response rate | “51%” |
| Median duration of response, months (range) | “9.7 (3, 52+)” |
| Responders with duration of 12 months or longer | “46%” |

Source: [Adstiladrin prescribing information (2026)](https://www.fda.gov/media/164029/download)

<a id="topic-2.1.2.14-6"></a>

### Nogapendekin alfa inbakicept: indication, dosing, and efficacy in prescribing information

| Feature | Quoted label text |
| --- | --- |
| Indication | “ANKTIVA, in combination with Bacillus Calmette-Guérin (BCG) is indicated for the treatment of adult patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC).” |
| Induction | “400 mcg administered intravesically with BCG once a week for 6 weeks.” |
| Maintenance | “400 mcg administered intravesically with BCG once a week for 3 weeks at months 4, 7, 10, 13 and 19.” |
| Bladder retention | “ANKTIVA in combination with BCG admixture should be retained in the bladder for 2 hours and then voided.” |
| Complete response rate (95% CI) | “62% (51, 73)” |
| Responders with duration of 12 months or longer | “58% (28)” |
| Responders with duration of 24 months or longer | “40% (19)” |

Source: [Anktiva prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761336s002lbl.pdf)

<a id="topic-2.1.2.14-7"></a>

### Gemcitabine intravesical system: indication, dosing, and efficacy in prescribing information

| Feature | Quoted label text |
| --- | --- |
| Indication | “INLEXZO is indicated for the treatment of adult patients with Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors.” |
| Dosing | “Insert INLEXZO (225 mg of gemcitabine) into the bladder once every 3 weeks up to 6 months (8 doses), followed by once every 12 weeks (6 doses).” |
| Insertion | “Insert into the bladder using the co-packaged urinary catheter and stylet only.” |
| Complete response rate (95% CI) | “82% (72, 90)” |
| Responders with duration of 12 months or longer | “51% (35)” |

Source: [Inlexzo prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219683s000lbl.pdf)

<a id="topic-2.1.2.14-8"></a>

### Pembrolizumab: indication, dosing, and efficacy in prescribing information

| Feature | Quoted label text |
| --- | --- |
| Indication | “KEYTRUDA, as a single agent, is indicated for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.” |
| Dosing | “200 mg every 3 weeks”; “400 mg every 6 weeks” |
| Duration of therapy | “Until persistent or recurrent high-risk NMIBC, disease progression, unacceptable toxicity, or up to 24 months” |
| Administration | “Administer KEYTRUDA as a 30-minute intravenous infusion.” |
| Complete response rate (95% CI) | “41% (31, 51)” |
| Median duration of response, months (range) | “16.2 (0.0+, 30.4+)” |
| Responders with duration of 12 months or longer | “46% (18)” |

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

Additional sources: [Colbert et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11961324/); [Heiss et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12363661/)

## Related pages
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Terms and abbreviations](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations.md)
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Product information and disease description](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Clinical evidence](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Economic information and modeling report](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: References](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references.md)
